Clinical Edge Journal Scan

Dietary phosphorus and risk for BC: Is there a link?


 

Key clinical point: This case-control study indicated that high dietary phosphorus intake (>1800 mg/day) almost doubled the risk for breast cancer (BC), thus warranting the evaluation of a low-phosphate diet in patients with BC.

Major finding: A high dietary phosphorus intake >1800 mg per day vs a low intake of 800-1000 mg per day was associated with an increased risk of developing BC (relative risk 2.30; P = .07).

Study details: This nested case-control study analyzed the data of 74 women with BC and 296 age-matched control individuals from the Study of Women’s Health Across the Nation, USA.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Brown RB et al. High dietary phosphorus is associated with increased breast cancer risk in a U.S. cohort of middle-age women. Nutrients. 2023;15(17):3735 (Aug 25). doi: 10.3390/nu15173735

Recommended Reading

Exercise tied to lower mortality risk across cancer types
MDedge Hematology and Oncology
Luminal A BC patients can skip radiotherapy after breast-conserving surgery
MDedge Hematology and Oncology
Giredestrant shows promising outcomes in HR+ /HER2− BC in phase 2 study
MDedge Hematology and Oncology
Metastatic BC: Meaningful clinical benefit with trifluridine/tipiracil in phase 2 study
MDedge Hematology and Oncology
TNBC: Greater efficacy of neoadjuvant apatinib + dose-dense paclitaxel + carboplatin vs dose-dense paclitaxel + carboplatin
MDedge Hematology and Oncology
High temporal and spatial resolution improves BC detection in women with high background parenchymal enhancement
MDedge Hematology and Oncology
BRCA-altered TNBC: High-dose alkylating chemotherapy fails to show improvement in phase 3 study
MDedge Hematology and Oncology
Adjuvant ET lowers distant metastases risk in ER+ /HER2− T1a/bN0M0 BC
MDedge Hematology and Oncology
Risk for major ischemic events in BC patients receiving radiotherapy
MDedge Hematology and Oncology
Post-diagnostic use of statins and metformin improves survival rates in BC
MDedge Hematology and Oncology